Celldex Therapeutics Bolsa (NASDAQ: CLDX)

Celldex Therapeutics (NASDAQ:CLDX) Bolsa

CELLDEX THERAPEUTICS INC

Celldex Therapeutics

Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics Inc

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) with a Buy and maintains $50 price target.

News

Price Target

Reiteration

Analyst Ratings

CLDX

HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $50 Price Target

Celldex Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company's Phase 2 clinical trial in chronic spontaneous urticaria (CSU). Angioedema, characterized by swelling of the deeper&nbsp;dermal&nbsp;layers of the skin and mucous&nbsp;membranes, is a painful, debilitating symptom of CSU that has significant impact on quality of life. It commonly affects the face (lips and eyelids), hands, feet, and&nbsp;genitalia but can also involve the tongue, uvula, soft&nbsp;palate, and&nbsp;pharynx1.
&nbsp;
Summary of Key Findings:
<ul>
<li>Patients on study had severe CSU. Over 70% of patients had a weekly urticaria activity score (UAS7) greater than 28 at baseline and reported very high rates of angioedema at baseline.</li>
<li>Barzolvolimab demonstrated rapid, robust and durable improvements in angioedema symptoms over the treatment period. At Week 52, an 86% mean reduction from baseline was reported for 150 mg Q4W arm and an 82% reduction was reported for the 300 mg Q8W.</li>
<li>Up to 77% of patients treated with barzolvolimab who had angioedema at baseline were angioedema free (AAS7=0) at Week 52.</li>
<li>Patients treated with barzolvolimab were angioedema free up to 72% of the time over the 52 week treatment period.</li>
<li>Up to 87% of patients reported clinically meaningful improvement (&gt;8 point) in AAS7 at Week 52.</li>
</ul>

Celldex On Saturday Announced 77% Of Patients Treated With Barzolvolimab Who Had Angioedema At Baseline Were Angioedema Free At Week 52

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 1% on Friday.
The Dow traded down 1.17% to 42,465.24 while the NASDAQ dipped 0.55% to 19,554.01. The S&amp;P 500 also fell, dropping, 0.54% to 6,012.88.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/45922932/top-3-tech-stocks-that-are-preparing-to-pump-this-quarter-2">Top 3 Tech Stocks That Are Preparing To Pump This Quarter</a>
Leading and Lagging Sectors Energy shares jumped by 1.3% on Friday.
In trading on Friday, financial stocks fell by 2.1%.
Top Headline
The University of Michigan's consumer sentiment index increased to 60.5 in June from 52.2 in the previous two months, and also topping market estimates of 53.5.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Unusual Machines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UMAC#NYSE">UMAC</a>) shares shot up 12% to $9.21 after the company agreed to acquire Rotor Lab in all-stock deal valued at $7 million. The company also announced termination of definitive agreement to acquire Aloft.</li>
<li>Shares of RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) got a boost, surging 18% to $207.97 after the company reported better-than-expected first-quarter adjusted EPS results and announced it is maintaining its current FY25 guidance despite tariff and macroeconomic event uncertainty.</li>
<li>Celldex Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) shares were also up, gaining 17% to $23.70 as the company announced 76-week results from Barzolvolimab Phase 2 study in chronic spontaneous urticaria at EAACI Congress 2025.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>SharpLink Gaming, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) shares dropped 66% to $11.11. SharpLink Gaming, announced the strategic acquisition of 176,270.69 ETH for an aggregate purchase price of $462,947,816 (inclusive of fees and expenses), at an average acquisition price of $2,626 per ETH (inclusive of fees and expenses).</li>
<li>Shares of Senmiao Technology Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIHS#NASDAQ">AIHS</a>) were down 39% to $0.63. Senmiao Technology on Friday announced a strategic partnership with Changsha Yipeng Information Technology Co., Ltd. to develop an AI-backed data management system to improve efficiency of online ride-hailing management platforms.</li>
<li>Chanson International Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHSN#NASDAQ">CHSN</a>) was down, falling 51% to $0.2711 as the company announced the pricing of $8 million public offering.</li>
</ul>
Commodities In commodity news, oil traded up 6.1% to $72.11 while gold traded up 1.6% at $3,456.60.
Silver traded down 0.2% to $36.220 on Friday, while copper fell 1.9% to $4.7445.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.86%, while Spain's IBEX 35 Index fell 1.58%. London's FTSE 100 declined 0.34%, Germany's DAX 40 fell 1.21% and France's CAC 40 dipped 1.05% during the session.
Asia Pacific Markets
Asian markets closed lower on Friday, with Japan's Nikkei falling 0.89%, Hong Kong's Hang Seng Index dipping 0.59%, China's Shanghai Composite declining 0.75% and India's BSE Sensex dipping 0.70%.
Economics
The University of Michigan's consumer sentiment index increased to 60.5 in June from 52.2 in the previous two months, and also topping market estimates of 53.5.
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/06/45923645/wall-streets-most-accurate-analysts-give-their-take-on-3-risk-off-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Risk Off Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

AIHS

CHSN

SBET

UMAC

Crude Oil Rises 6%; US Consumer Sentiment Surges In June

U.S. stocks were lower, with the Dow Jones index falling around 600 points on Friday.
Shares of Unusual Machines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UMAC#NYSE">UMAC</a>) rose sharply during Friday's session after the company agreed to acquire Rotor Lab in all-stock deal valued at $7 million. The company also announced termination of definitive<a href="https://www.benzinga.com/quote/UMAC"> agreement to acquire Aloft.</a>
Unusual Machines shares jumped 19.5% to $9.85 on Friday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) shares jumped 22.8% to $217.17 after the company reported better-than-expected first-quarter adjusted EPS results and announced it is maintaining its current FY25 guidance despite tariff and macroeconomic event uncertainty.</li>
<li>AleAnna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANNA#NASDAQ">ANNA</a>) gained 18.3% to $10.40.</li>
<li>Columbus Circle Capital Corp I (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCCM#NASDAQ">CCCM</a>) rose 13.5% to $11.95.</li>
<li>Darling Ingredients Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAR#NYSE">DAR</a>) surged 11.4% to $35.08.</li>
<li>Maase Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAAS#NASDAQ">MAAS</a>) rose 11.1% to $3.00.</li>
<li>Sasol Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSL#NYSE">SSL</a>) gained 10.8% to $5.38.</li>
<li>Celldex Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) climbed 9.9% to $22.36 as the company announced 76-week results from Barzolvolimab Phase 2 study in chronic spontaneous urticaria at EAACI Congress 2025.</li>
<li>UroGen Pharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URGN#NASDAQ">URGN</a>) rose 8.4% to $12.01. UroGen Pharma shares traded higher on Thursday after the FDA approved ZUSDURI for intravesical solution as the first and only medication for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.</li>
<li>DoubleDown Interactive Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDI#NASDAQ">DDI</a>) gained 6.9% to $8.71. DoubleDown Interactive recently announced the pricing of its secondary offering of 4,347,827 ADS by selling shareholders at $8.50 per ADS.</li>
<li>Kosmos Energy Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KOS#NYSE">KOS</a>) gained 6.7% to $2.2309.</li>
<li>Phathom Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAT#NASDAQ">PHAT</a>) gained 5.5% to $10.58.</li>
<li>Bunge Global SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BG#NYSE">BG</a>) rose 5% to $80.89.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45924005/top-2-energy-stocks-that-may-fall-off-a-cliff-in-june">Top 2 Energy Stocks That May Fall Off A Cliff in June</a> </li>
</ul>
Photo via Shutterstock

Movers

ANNA

CCCM

Highest Performances Holdings Inc. - American Depository Shares

MAAS

PHAT

URGN

Unusual Machines, Celldex Therapeutics, RH And Other Big Stocks Moving Higher On Friday

Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) in the last three months.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $50.25, a high estimate of $80.00, and a low estimate of $31.00. This current average represents a 10.27% decrease from the previous average price target of $56.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1749816058_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Celldex Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Trung Huynh</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$38.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Richard Law</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$31.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Judah Frommer</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$43.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$50.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Edward Nash</td>
<td>Canaccord Genuity</td>
<td>Announces</td>
<td>Buy</td>
<td>$64.00</td>
<td>-</td>
</tr>
<tr>
<td>Judah Frommer</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Overweight</td>
<td>$46.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Celldex Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Celldex Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Celldex Therapeutics's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CLDX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Celldex Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Celldex Therapeutics Better</h2>
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
<h3>Financial Insights: Celldex Therapeutics</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Celldex Therapeutics's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 345.51%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Celldex Therapeutics's net margin excels beyond industry benchmarks, reaching -7740.43%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Celldex Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -7.42% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Celldex Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -7.02%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Celldex Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.0.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 8 Analyst Projections For Celldex Therapeutics

General

Celldex Therapeutics Announces 76-Week Results From Barzolvolimab Phase 2 Study In Chronic Spontaneous Urticaria At EAACI Congress 2025; Up To 41% Of Patients Reporting A Complete Response At 76 Weeks And 48% Of Patients Reporting That Their Disease No Longer Impacts Their Quality Of Life; Enrollment to Phase 3 CSU Trials Ongoing

Celldex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) announced today that data from the Company's Phase 2 study of barzolvolimab in chronic spontaneous urticaria will be presented at the EAACI Congress 2025 being held in Glasgow, Scotland. Abstracts will be available on the meeting website Thursday, June 12th at 6:01 pm ET/ Friday, June 13th at 12:01 am CEST. Celldex will host a webcast on Thursday, June 12th at 6:00 pm ET to discuss the data.

Celldex To Present Data From Phase 2 Study Of Barzolvolimab In Chronic Spontaneous Urticaria At EAACI Congress 2025

UBS analyst Trung Huynh maintains Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) with a Buy and lowers the price target from $44 to $38.

UBS Maintains Buy on Celldex Therapeutics, Lowers Price Target to $38

Goldman Sachs analyst Richard Law maintains Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) with a Neutral and lowers the price target from $36 to $31.

Goldman Sachs Maintains Neutral on Celldex Therapeutics, Lowers Price Target to $31

Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) with a Overweight and lowers the price target from $46 to $43.

Morgan Stanley Maintains Overweight on Celldex Therapeutics, Lowers Price Target to $43

HC Wainwright &amp; Co. analyst Joseph Pantginis maintains Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) with a Buy and lowers the price target from $80 to $50.

HC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Lowers Price Target to $50

Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) reported quarterly losses of $(0.81) per share which missed the analyst consensus estimate of $(0.74) by 9.46 percent. This is a 44.64 percent decrease over losses of $(0.56) per share from the same period last year. The company reported quarterly sales of $695.00 thousand which missed the analyst consensus estimate of $1.05 million by 33.59 percent. This is a 345.51 percent increase over sales of $156.00 thousand the same period last year.

Earnings Misses

Celldex Therapeutics Q1 EPS $(0.81) Misses $(0.74) Estimate, Sales $695.00K Miss $1.05M Estimate

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) with a Buy and maintains $80 price target.

HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $80 Price Target

Biotech

Events

Celldex Presents Histology Data From Phase 2 Study Of Barzolvolimab In EoE

Across the recent three months, 7 analysts have shared their insights on Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $59.57, with a high estimate of $80.00 and a low estimate of $36.00. Highlighting a 11.42% decrease, the current average has fallen from the previous average price target of $67.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1745845243_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Celldex Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Edward Nash &#x7C;Canaccord Genuity &#x7C;Announces &#x7C;Buy &#x7C; $64.00&#x7C;- &#x7C; 
&#x7C;Judah Frommer &#x7C;Morgan Stanley &#x7C;Announces &#x7C;Overweight &#x7C; $46.00&#x7C;- &#x7C; 
&#x7C;Richard Law &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Neutral &#x7C; $36.00&#x7C;$42.00 &#x7C; 
&#x7C;Joseph Pantginis &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $80.00&#x7C;$80.00 &#x7C; 
&#x7C;Joseph Pantginis &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $80.00&#x7C;$80.00 &#x7C; 
&#x7C;Trung Huynh &#x7C;UBS &#x7C;Announces &#x7C;Buy &#x7C; $44.00&#x7C;- &#x7C; 
&#x7C;Kristen Kluska &#x7C;Cantor Fitzgerald &#x7C;Maintains &#x7C;Overweight &#x7C; $67.00&#x7C;$67.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Celldex Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Celldex Therapeutics compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Celldex Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Celldex Therapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CLDX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Celldex Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Celldex Therapeutics</h2>
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
<h3>Celldex Therapeutics's Economic Impact: An Analysis</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Celldex Therapeutics's revenue growth over a period of 3M has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -71.56%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -4007.83%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Celldex Therapeutics's ROE excels beyond industry benchmarks, reaching -6.14%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Celldex Therapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -5.83%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Celldex Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Celldex Therapeutics's Future

Top Wall Street analysts initiated coverage on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Canaccord Genuity analyst Edward Nash initiated coverage on Celldex Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) with a Buy rating and announced a price target of $64. Celldex Therapeutics shares closed at $19.57 on Friday. <a href="https://www.benzinga.com/quote/CLDX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Michael Mueller initiated coverage on SmartStop Self Storage REIT, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMA#NYSE">SMA</a>) with an Overweight rating and announced a price target of $36. Smartstop Self Storage shares closed at $33.45 on Friday. <a href="https://www.benzinga.com/quote/SMA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Paul Kearney initiated coverage on Kohl&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) with an Underweight rating and announced a price target of $4. Kohl&#8217;s shares closed at $7.06 on Friday. <a href="https://www.benzinga.com/quote/KSS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo initiated coverage on Zillow Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>) with an Equal-Weight rating and announced a price target of $62. Zillow shares closed at $65.19 on Friday. <a href="https://www.benzinga.com/quote/ZG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>D. Boral Capital analyst Jason Kolbert initiated coverage on Co-Diagnostics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODX#NASDAQ">CODX</a>) with a Buy rating and announced a price target of $10. Co-Diagnostics shares closed at $0.35 on Friday.  <a href="https://www.benzinga.com/quote/CODX/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying KSS stock? Here&#8217;s what analysts think:
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="591" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28080117/image-194-1024x591.png" alt="" class="wp-image-890712" style="width:606px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28080117/image-194-1024x591.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28080117/image-194-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28080117/image-194-768x443.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28080117/image-194.png 1157w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45035424/top-3-health-care-stocks-that-may-rocket-higher-in-april">Top 3 Health Care Stocks That May Rocket Higher In April</a> </li>
</ul>
Photo via Shutterstock

Initiation

Pre-Market Outlook

CODX

This Kohl's Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday

Canaccord Genuity analyst Edward Nash initiates coverage on Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) with a Buy rating and announces Price Target of $64.

Canaccord Genuity Initiates Coverage On Celldex Therapeutics with Buy Rating, Announces Price Target of $64

In the last three months, 7 analysts have published ratings on Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>), offering a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $60.0, along with a high estimate of $80.00 and a low estimate of $36.00. A 10.71% drop is evident in the current average compared to the previous average price target of $67.20. 
<img src="https://www.benzinga.com/files/images/story/2025/1742508047_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A clear picture of Celldex Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Judah Frommer</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Overweight</td>
<td>$46.00</td>
<td>-</td>
</tr>
<tr>
<td>Richard Law</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$36.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Trung Huynh</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$44.00</td>
<td>-</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$67.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$67.00</td>
<td>$67.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Celldex Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Celldex Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Celldex Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Celldex Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CLDX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Celldex Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Celldex Therapeutics</h2>
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
<h3>Financial Insights: Celldex Therapeutics</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Celldex Therapeutics faced challenges, resulting in a decline of approximately -71.56% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Celldex Therapeutics's net margin excels beyond industry benchmarks, reaching -4007.83%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Celldex Therapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -6.14%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Celldex Therapeutics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -5.83%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Celldex Therapeutics's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

7 Analysts Have This To Say About Celldex Therapeutics

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>B. Riley Securities analyst Kalpit Patel initiated coverage on ArriVent BioPharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVBP#NASDAQ">AVBP</a>) with a Buy rating and announced a price target of $37. ArriVent BioPharma shares closed at $19.60 on Wednesday. <a href="https://www.benzinga.com/quote/AVBP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Noah Poponak initiated coverage on Amentum Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMTM#NYSE">AMTM</a>) with a Neutral rating and announced a price target of $21. Amentum Holdings shares closed at $19.03 on Wednesday. <a href="https://www.benzinga.com/quote/ANTM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Judah Frommer initiated coverage on Celldex Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) with an Overweight rating and announced a price target of $46. Celldex Therapeutics shares closed at $19.95 on Wednesday. <a href="https://www.benzinga.com/quote/CLDX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Detlef Winckelmann initiated coverage on International Paper Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IP#NYSE">IP</a>) with an Overweight rating and announced a price target of $59. International Paper shares closed at $52.62 on Wednesday. <a href="https://www.benzinga.com/quote/IP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Scotiabank analyst Patrick Colville initiated coverage on Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) with a Sector Outperform rating and announced a price target of $470. Microsoft shares closed at $387.82 on Wednesday. &nbsp;<a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying MSFT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="568" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/20095446/image-182-1024x568.png" alt="" class="wp-image-833840" style="width:465px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/20095446/image-182-1024x568.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/20095446/image-182-300x166.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/20095446/image-182-768x426.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/20095446/image-182.png 1133w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44396642/jim-cramer-says-tjx-is-terrific-recommends-buying-these-stocks">Jim Cramer Says TJX Is &#8216;Terrific,&#8217; Recommends Buying These Stocks</a></li>
</ul>
Photo: Shutterstock

AMTM

AVBP

MSFT

This Microsoft Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Press Releases

Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025

Health Care

Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025

Celldex Therapeutics to Present at Upcoming Investor Conferences

Celldex Therapeutics and Agios Pharmaceuticals to Present at March 2025 Investor Conferences

Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease

Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update

Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors

Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress

Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025

Comments

Celldex Therapeutics

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL